Literature DB >> 17277229

Genetic variability in prostaglandin synthesis, fish intake and risk of colorectal polyps.

Elizabeth M Poole1, Jeannette Bigler, John Whitton, Justin G Sibert, Richard J Kulmacz, John D Potter, Cornelia M Ulrich.   

Abstract

Dietary polyunsaturated fatty acids (PUFAs) can be converted to prostaglandins and leukotrienes. Metabolism of omega-6 (n-6) PUFAs results in the production of pro-inflammatory mediators whereas downstream products of omega-3 (n-3) PUFAs have lower inflammatory activity. Elevated n-3 PUFA intake from dietary fish may be associated with lower risk of colorectal neoplasia among those with genetic variants resulting in higher levels of pro-inflammatory mediators. We investigated interactions between dietary fish intake and polymorphisms in cyclooxygenase (COX)-1, COX-2, ALOX5 and PGIS in a case-control study of adenomas (N = 522), hyperplastic polyps (N = 194) and polyp-free controls (N = 626). Polyp risk did not differ by fish intake. A suggested interaction with fish intake was observed for COX-1 P17L. Among those who were homozygous wild type, increasing fish intake was associated with a modestly reduced risk of adenoma, whereas among those with at least one variant allele, the reverse trend was observed (p-interaction = 0.08). The interaction was statistically significant when non-steroidal anti-inflammatory drug (NSAID) use was also taken into account: among those with COX-1 17PP genotypes, high fish intake and regular NSAID use was associated with a decreased risk compared with low fish intake and low NSAID use (odds ratio = 0.60, 95% confidence interval 0.33-1.09). The opposite association was observed among those with COX-1 17PL or LL genotypes (p-interaction = 0.04). Our results suggest that the effects of dietary n-3 PUFA intake and NSAID use may differ by genetic variation in COX-1.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17277229     DOI: 10.1093/carcin/bgm026

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  18 in total

Review 1.  Enzymes of the cyclooxygenase pathways of prostanoid biosynthesis.

Authors:  William L Smith; Yoshihiro Urade; Per-Johan Jakobsson
Journal:  Chem Rev       Date:  2011-09-27       Impact factor: 60.622

2.  COX-1 (PTGS1) and COX-2 (PTGS2) polymorphisms, NSAID interactions, and risk of colon and rectal cancers in two independent populations.

Authors:  Karen W Makar; Elizabeth M Poole; Alexa J Resler; Brenna Seufert; Karen Curtin; Sarah E Kleinstein; David Duggan; Richard J Kulmacz; Li Hsu; John Whitton; Christopher S Carlson; Christine F Rimorin; Bette J Caan; John A Baron; John D Potter; Martha L Slattery; Cornelia M Ulrich
Journal:  Cancer Causes Control       Date:  2013-12       Impact factor: 2.506

3.  Long-chain omega-3 polyunsaturated fatty acid intake and risk of colorectal cancer.

Authors:  Elizabeth D Kantor; Johanna W Lampe; Ulrike Peters; Thomas L Vaughan; Emily White
Journal:  Nutr Cancer       Date:  2013-09-20       Impact factor: 2.900

4.  Genetic variation in prostaglandin synthesis and related pathways, NSAID use and colorectal cancer risk in the Colon Cancer Family Registry.

Authors:  Alexa J Resler; Karen W Makar; Laura Heath; John Whitton; John D Potter; Elizabeth M Poole; Nina Habermann; Dominique Scherer; David Duggan; Hansong Wang; Noralane M Lindor; Michael N Passarelli; John A Baron; Polly A Newcomb; Loic Le Marchand; Cornelia M Ulrich
Journal:  Carcinogenesis       Date:  2014-06-07       Impact factor: 4.944

5.  Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma.

Authors:  Elizabeth M Poole; Li Hsu; Liren Xiao; Richard J Kulmacz; Christopher S Carlson; Peter S Rabinovitch; Karen W Makar; John D Potter; Cornelia M Ulrich
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-01-19       Impact factor: 4.254

6.  Impact of genetic polymorphisms on adenoma recurrence and toxicity in a COX2 inhibitor (celecoxib) trial: results from a pilot study.

Authors:  Sarah Kraus; Simone Hummler; Nadir Arber; Cornelia M Ulrich; Adetunji T Toriola; Elizabeth M Poole; Dominique Scherer; Jana Kotzmann; Karen W Makar; Dina Kazanov; Lior Galazan; Inna Naumov; Anna E Coghill; David Duggan; Biljana Gigic
Journal:  Pharmacogenet Genomics       Date:  2013-08       Impact factor: 2.089

7.  IκBKβ and NFκB1, NSAID use and risk of colorectal cancer in the Colon Cancer Family Registry.

Authors:  Brenna L Seufert; Elizabeth M Poole; John Whitton; Liren Xiao; Karen W Makar; Peter T Campbell; Richard J Kulmacz; John A Baron; Polly A Newcomb; Martha L Slattery; John D Potter; Cornelia M Ulrich
Journal:  Carcinogenesis       Date:  2012-09-22       Impact factor: 4.944

8.  Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial.

Authors:  Elizabeth L Barry; Leah B Sansbury; Maria V Grau; Iqbal U Ali; Shirley Tsang; David J Munroe; Dennis J Ahnen; Robert S Sandler; Fred Saibil; Jiang Gui; Robert S Bresalier; Gail E McKeown-Eyssen; Carol Burke; John A Baron
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-09-15       Impact factor: 4.254

9.  Genetic variation in the lipoxygenase pathway and risk of colorectal neoplasia.

Authors:  Sarah E Kleinstein; Laura Heath; Karen W Makar; Elizabeth M Poole; Brenna L Seufert; Martha L Slattery; Liren Xiao; David J Duggan; Li Hsu; Karen Curtin; Lisel Koepl; Jill Muehling; Darin Taverna; Bette J Caan; Christopher S Carlson; John D Potter; Cornelia M Ulrich
Journal:  Genes Chromosomes Cancer       Date:  2013-02-12       Impact factor: 5.006

10.  Dietary omega-3 fatty acids, cyclooxygenase-2 genetic variation, and aggressive prostate cancer risk.

Authors:  Vincent Fradet; Iona Cheng; Graham Casey; John S Witte
Journal:  Clin Cancer Res       Date:  2009-03-24       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.